HC Wainwright & Co. Downgrades Terns Pharma to Neutral, Lowers Price Target to $53

Benzinga Newsdesk www.benzinga.com Negative 88.6%

Neg 88.6% Neu 0% Pos 0%

HC Wainwright & Co. analyst Andres Y. Maldonado downgrades Terns Pharma (NASDAQ:TERN) from Buy to Neutral and lowers the price target from $60 to $53.